Low-density lipoprotein apheresis can improve type AA systemic amyloidosis.
Iwahori
T
T
Yoshida
M
M
D000328:Adult; D000686:Amyloidosis / Q000097:blood / Q000473:pathology / Q000628:therapy*; D001781:Blood Component Removal; D001806:Blood Urea Nitrogen; D002097:C-Reactive Protein / Q000032:analysis; D003404:Creatinine / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000473:pathology / Q000628:therapy*; D007678:Kidney Glomerulus / Q000473:pathology; D008077:Lipoproteins, LDL / Q000097:blood* / Q000302:isolation & purification; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D000685:Serum Amyloid A Protein / Q000032:analysis*
D008077:Lipoproteins, LDL; D000685:Serum Amyloid A Protein; D002097:C-Reactive Protein; D011239:Prednisolone; D003404:Creatinine